Patent: 9,775,904
✉ Email this page to a colleague
Summary for Patent: 9,775,904
Title: | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
Abstract: | The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake. |
Inventor(s): | Bossart; Martin (Frankfurt am Main, DE), Elvert; Ralf (Frankfurt am Main, DE), Evers; Andreas (Frankfurt am Main, DE), Haack; Torsten (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE), Wagner; Michael (Frankfurt am Main, DE) |
Assignee: | SANOFI (Paris, FR) |
Application Number: | 14/679,743 |
Patent Claims: | see list of patent claims |
Details for Patent 9,775,904
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 10/28/1982 | ⤷ Try a Trial | 2034-04-07 |
Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | 12/29/2015 | ⤷ Try a Trial | 2034-04-07 |
Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 08/06/1998 | ⤷ Try a Trial | 2034-04-07 |
Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | 03/31/1994 | ⤷ Try a Trial | 2034-04-07 |
Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 05/25/2018 | ⤷ Try a Trial | 2034-04-07 |
Novo Nordisk Inc. | NOVOLIN R | insulin human | Injection | 019938 | 06/25/1991 | ⤷ Try a Trial | 2034-04-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |